Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials

被引:23
|
作者
Wang, Hao-tian [1 ]
Wang, Li [2 ,3 ]
He, Yi [1 ]
Yu, Gang [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, 1 Youyi Rd, Chongqing 400016, Peoples R China
[2] Chongqing Univ, Canc Hosp, Dept Hematooncol, Chongqing, Peoples R China
[3] Chongqing Canc Hosp, Chongqing Canc Inst, Chongqing, Peoples R China
基金
美国国家科学基金会;
关键词
Parkinson's disease; Rotigotine transdermal patch; Neuropsychiatric symptoms; Meta-analysis; DOUBLE-BLIND; DEPRESSION; QUESTIONNAIRE; PRAMIPEXOLE; ANHEDONIA; AGONIST; SCALES;
D O I
10.1016/j.jns.2018.08.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To systematically evaluate and quantify the effects of rotigotine treatment on neuropsychiatric symptoms in Parkinson's disease (PD). Methods: We searched for articles involving randomized controlled trials (RCTs) that were published before September 1, 2017, in the PubMed, Clinical Trials, Cochrane Library, and EMBASE databases. A meta-analysis was performed to estimate changes in the scales used to assess neuropsychiatric symptoms. The data were analyzed using Cochrane Collaboration's Review Manager 5.3 software. Results: We identified 8 RCTs involving 1675 subjects. Compared with placebo treatment, treatment with the rotigotine transdermal patch significantly improved scores for the emotion/apathy domains of the Non-Motor Symptoms Scale (NMSS), Beck Depression Inventory-II (BDI-II), Apathy Scale (AS), the sleep/fatigue domains of the NMSS, the 8-item Parkinson's disease Questionnaire (PDQ-8) and the 39-item PDQ (PDQ-39) (emotion/apathy domain of the NMSS: MD = -2.5, 95% CI [-4.11, 0.89]; BDI-II: MD = -1.19, 95% CI [-2.30, 0.08]; AS: MD = -1.56, 95% CI [-2.67, 0.45]; sleep/fatigue domain of the NMSS: MD = 2.03, 95% CI [3.08, 0.98]; PDQ-8: MD = -4.93, 95% CI [-6.79, 3.07]; PDQ-39: MD = -3.52, 95% CI [-5.25, 1.79]; PDQ-8 and PDQ-39: SMD = -0.36,95% CI [0.49,0.23]). The results of the Parkinson's Disease Sleep Scale 2nd version (PDSS-2) were heterogeneous, and those on the Snaith-Hamilton Pleasure Scale (SHAPS) were not statistically significant (P = .61). Conclusion: The rotigotine transdermal patch effectively improved neuropsychiatric symptoms and quality of life in patients with PD. Further studies are warranted.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 50 条
  • [1] Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson's Disease: An Updated Meta-Analysis and Systematic Review
    Yan, Junqiang
    Ma, Hongxia
    Liu, Anran
    Huang, Jiarui
    Wu, Jiannan
    Yang, Jianxue
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [2] Rotigotine Transdermal Patch in Parkinson's Disease: A Systematic Review and Meta-Analysis
    Zhou, Chang-Qing
    Li, Shan-Shan
    Chen, Zhong-Mei
    Li, Feng-Qun
    Lei, Peng
    Peng, Guo-Guang
    PLOS ONE, 2013, 8 (07):
  • [3] Rotigotine in the treatment of primary restless legs syndrome: A meta-analysis of randomized placebo-controlled trials
    Jun Ding
    Wei Fan
    Hong-hui Chen
    Peng Yan
    Sheng-gang Sun
    Jin Zheng
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35 : 169 - 175
  • [4] Rotigotine in the Treatment of Primary Restless Legs Syndrome: A Meta-analysis of Randomized Placebo-controlled Trials
    Ding, Jun
    Fan, Wei
    Chen, Hong-hui
    Yan, Peng
    Sun, Sheng-gang
    Zheng, Jin
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2015, 35 (02) : 169 - 175
  • [5] Rotigotine in the Treatment of Primary Restless Legs Syndrome:A Meta-analysis of Randomized Placebo-controlled Trials
    丁君
    范威
    陈红辉
    闫鹏
    孙圣刚
    郑瑾
    Current Medical Science, 2015, (02) : 169 - 175
  • [6] The efficacy and safety of rotigotine transdermal patch for the treatment of sleep disorders in Parkinson's disease: a meta-analysis
    Fei, Lu
    Zhou, Dao
    Ding, Zheng-Tong
    SLEEP MEDICINE, 2019, 61 : 19 - 25
  • [7] Treatment of nocturnal symptoms of Parkinson's disease using rotigotine transdermal patch
    Chaudhuri, K. Ray
    Jankovic, Joseph
    Trenkwalder, Claudia
    Boroojerdi, Babak
    ANNALS OF NEUROLOGY, 2007, 62 : S36 - S36
  • [8] Treatment of nocturnal symptoms of Parkinson's disease using rotigotine Transdermal patch
    Chaudhuri, R.
    Jankovic, J.
    Trenkwalder, C.
    Boroojerdi, B.
    MOVEMENT DISORDERS, 2007, 22 (12) : VI - VI
  • [9] Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Nomoto, Masahiro
    Mizuno, Yoshikuni
    Kondo, Tomoyoshi
    Hasegawa, Kazuko
    Murata, Miho
    Takeuchi, Masahiro
    Ikeda, Junji
    Tomida, Takayuki
    Hattori, Nobutaka
    JOURNAL OF NEUROLOGY, 2014, 261 (10) : 1887 - 1893
  • [10] Rotigotine transdermal patch for the treatment of Parkinson's Disease
    Perez-Lloret, Santiago
    Rey, Maria Veronica
    Ratti, Pietro Lucca
    Rascol, Olivier
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 (01) : 81 - 95